Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 271

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 271
---
 regardless of fault or a covered officer’s
role in the financial reporting process. The Compensation Recovery Policy is filed as Exhibit 97.1 to our Annual Report on Form 10-K
for the year ended December 31, 2023.

Rule 10b5-1 Sales Plans

Our directors and executive
officers may adopt written plans, known as Rule 10b5-1 plans, in which they will contract with a broker to buy or sell shares of
common stock on a periodic basis. Under a Rule 10b5-1 plan, a broker executes trades pursuant to parameters established by the director
or executive officer when entering into the plan, without further direction from them. The director or executive officer may amend a
Rule 10b5-1 plan in some circumstances and may terminate a plan at any time. Our directors and executive officers also may buy or
sell additional shares outside of a Rule 10b5-1 plan when they are not in possession of material nonpublic information, subject
to compliance with the terms of the insider trading policy.

<div align='center'>158

DIRECTOR COMPENSATION</div>

None of our directors received
compensation in 2023 for services rendered to PBAX or Legacy CERo, with the exception of Dr. Corey, who was compensated for his service
as our Chief Executive Officer. Dr. Corey was a named executive officer and his compensation is provided in the “Summary Compensation Table” above.

On March 25, 2024, the board
of directors approved the compensation for non-employee directors for 2024. Each non-employee director will receive $30,000 per annum,
paid quarterly in advance. In addition, each non-employee director other than the vice chairman shall receive an option award to purchase
1,125 shares of common stock. Such option awards vest quarterly over a three-year period and expire ten years after the grant date. The
vice chairman will receive $150,000 per annum, paid quarterly in advance. In addition, the vice chairman shall receive an option award
to purchase 5,272 shares of common stock. Such option awards vest quarterly over a three-year period and expire ten years after the grant
date.

On September 30, 2024, the
board of directors approved the grant of 2,550 options to each of our non-employee directors, which will vest (i) 50% upon the FDA’s
acceptance of our IND and (ii